Therapeutics News and Research

RSS

Chromosomal instability may predict which patients will respond better to colorectal cancer drug

Researchers at RCSI, along with international collaborators within the ANGIOPREDICT research consortium, have discovered that chromosomal instability (where whole human chromosomes or parts of chromosomes are duplicated or deleted) may predict which patients will receive most benefit from a key drug used to treat colorectal cancer (Avastin).

10 Oct 2018

Synedgen announces market launch of Moisyn Rinse for treatment of dry mouth symptoms

Synedgen, a company leveraging its proprietary glycomics technology platform to develop glycopolymer-based therapeutics for infectious and inflammatory conditions, today announced the market launch of Moisyn Rinse for the treatment of the symptoms of xerostomia, or dry mouth. Moisyn Rinse is being distributed by Prisyna, the oral care division of Synedgen.

10 Oct 2018

CDC’s Systemic Review analyzes HIV-related stigma among US healthcare providers

A Systemic Review from the U.S. Centers for Disease Control and Prevention analyzed studies of HIV-related stigma among healthcare provider and identified three main themes: attitudes, beliefs, and behaviors; quality of patient care; and education and training.

10 Oct 2018

Antibody Screening Tools; Improving Workflows

Antibody screening tools have exponentially increased the rate that candidates can be screened, multiplexing will increase processing to thousands per hour.¬

From Sartorius 9 Oct 2018

New pre-clinical research shows utility of mRNA platform to treat rare metabolic disorders

An mRNA platform that can express therapeutic levels of protein in liver tissue could be used to treat patients with rare metabolic disorders.

9 Oct 2018

Researchers design new method to pinpoint genetic differences between species

Why do naked mole rats live up to 31 years, when distantly related lab mice are lucky to make it to four? How is the aquatic axolotl capable of regenerating limbs, jaws, spines and even brains when frogs can only regrow tails as tadpoles? How can these difference be exploited for the benefit of human health?

8 Oct 2018

Lyra Therapeutics announces presentation of Phase 1 clinical data for LYR-210 in CRS patients

Lyra Therapeutics, Inc., a clinical-stage biotechnology company developing medicines precisely designed to target ear, nose and throat diseases, today announced the presentation of Phase 1 clinical data for the company's lead therapeutic, LYR-210, for chronic rhinosinusitis, a debilitating disease caused by inflammation of the paranasal sinus tissues that affects approximately 27 million people, or 11% of the adult population in the U.S.

8 Oct 2018

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, today announced promising results of the T-CALM Phase 2 clinical trial of its first-in-class T-type calcium channel modulator CX-8998 in essential tremor.

7 Oct 2018

Researchers receive $1.2 million grant to test potential treatment for metastatic breast cancer

A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.

5 Oct 2018

Studies needed on effects of cannabis use on physical health of children

McMaster University researchers say there is an urgent need for studies on the physical health effects of cannabis use, including its impact on puberty.

5 Oct 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

Bradford and GE Healthcare collaborate to build new AI-powered hospital Command Center in Europe

Bradford Teaching Hospitals NHS Foundation Trust is collaborating with GE Healthcare to build a Command Center - like an air traffic control - at the Bradford Royal Infirmary, UK. A first of its kind in Europe, the Command Center will transform how care is delivered and organized as the number of patients at the hospital continues to increase.

4 Oct 2018

Working with Next Health World Innovation Forum to build a healthier future

The Innovation Forum is partnering with the Milner Therapeutics Institute in 2019 for the Next Health World Innovation Forum – a new international healthcare conference taking place from 26-27 June 2019, in Cambridge, UK.

4 Oct 2018

Doctors use bacteriophages to treat patient with multi-drug resistant bacterial infection

The married professors were spending their Thanksgiving holiday in Egypt when the husband, Thomas L. Patterson, Ph.D., got very sick very quickly, experiencing fever, nausea and a racing heartbeat. By the time Patterson was accurately diagnosed with a highly multi-drug resistant bacterial infection, he was near death.

4 Oct 2018

Blocking stress-responsive protein reduces loss of tumor suppressor gene in breast cancer

Over half of all breast cancers carry genetic defects in the p53 gene, a powerful tumor suppressor. Loss of this gene increases the risk of getting breast cancer and the resultant cancers become highly resistant to treatment.

4 Oct 2018

Study: Reducing mutated Huntington disease protein restores psychiatric impairments in mice

New research from the University of British Columbia suggests that reducing mutated Huntington disease protein in the brain can restore cognitive and psychiatric impairments in mice.

4 Oct 2018

New ReFRAME drug repurposing collection offers hope for treating major diseases

Each year, millions of people worldwide suffer from potentially fatal infectious diseases that often leave survivors facing a lifetime of related health problems. But what if drugs against such diseases already existed but nobody knew it?

4 Oct 2018

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Genentech, a member of the Roche Group, announced today interim clinical data from the dose-finding parts of the pivotal FIREFISH and SUNFISH studies investigating risdiplam in spinal muscular atrophy.

3 Oct 2018

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today that it has submitted a Clinical Trial Authorization application to the Medicines and Healthcare products Regulatory Agency to initiate a Phase 1/2 study of ALN-AAT02, an investigational RNAi therapeutic targeting alpha-1 antitrypsin for the treatment of AAT deficiency-associated liver disease.

3 Oct 2018

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Therapure Biomanufacturing, an integrated contract development and manufacturing organization and a division of Therapure Biopharma Inc., today announced approval for the manufacturing of Insmed Incorporated's ARIKAYCE® at its Mississauga facility by the U.S. Food and Drug Administration.

3 Oct 2018

Therapeutics News and Research

Chromosomal instability may predict which patients will respond better to colorectal cancer drug

Synedgen announces market launch of Moisyn Rinse for treatment of dry mouth symptoms

CDC’s Systemic Review analyzes HIV-related stigma among US healthcare providers

Antibody Screening Tools; Improving Workflows

New pre-clinical research shows utility of mRNA platform to treat rare metabolic disorders

Researchers design new method to pinpoint genetic differences between species

Lyra Therapeutics announces presentation of Phase 1 clinical data for LYR-210 in CRS patients

T-CALM Phase 2 clinical study results offer hope for essential tremor patients

Researchers receive $1.2 million grant to test potential treatment for metastatic breast cancer

Studies needed on effects of cannabis use on physical health of children

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Bradford and GE Healthcare collaborate to build new AI-powered hospital Command Center in Europe

Working with Next Health World Innovation Forum to build a healthier future

Doctors use bacteriophages to treat patient with multi-drug resistant bacterial infection

Blocking stress-responsive protein reduces loss of tumor suppressor gene in breast cancer

Study: Reducing mutated Huntington disease protein restores psychiatric impairments in mice

New ReFRAME drug repurposing collection offers hope for treating major diseases

Genentech announces clinical data from studies investigating risdiplam in spinal muscular atrophy

Alnylam submits CTA application to MHRA to initiate Phase 1/2 study of ALN-AAT02

FDA approves manufacturing of Insmed's ARIKAYCE at Therapure Biopharma's Mississauga facility

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News